PD 161374

PD 161374 is an inhibitor targeting the HIV-1 nucleocapsid protein NCp7. PD 161374 primarily acts on the early stages of viral replication, inhibiting the completion of reverse transcription without affecting viral entry or later assembly. PD 161374 remains active against HIV-1, HIV-2, SIV, and drug-resistant strains. PD 161374 can be used to study antiretroviral agents^[1][2]. In Vitro:PD 161374 is effective against all tested HIV-1, HIV-2 and SIV strains, with the EC₅₀ range being between 1.3 and 9.5 μM and it is also effective against AZT and protease inhibitor-resistant strains^[1].
PD 161374 (48 h) effectively inhibits the infection of HeLa Magi cells by HIV when added within 0-4 hours after infection, but added 6 hours after infection, it completely lost its protective effect^[1].
PD 161374 (4-24 h) significantly delayed and disrupted the normal progression and completion of the reverse transcription process in H9 cells infected with HIV-1 IIIB, resulting in the inability of viral DNA to successfully enter the nucleus and circularize^[1].
PD 161374 (20 μM, 48 h) only slightly inhibits (20-40%) the release of the virus on chronically infected H9/HIV-III^[1].
PD 161374 shows an EC₅₀ of 1.3 µM and no cytotoxicity up to 100 µM in T cell culture^[2].
PD 161374 delays the appearance of completed HIV-cDNA products including 2-LTR circles^[2].